- Report
- October 2024
- 194 Pages
Global
From €3370EUR$3,545USD£2,831GBP
€3745EUR$3,939USD£3,146GBP
- Report
- October 2024
- 99 Pages
Global
From €3500EUR$3,944USD£3,043GBP
- Report
- March 2025
Global
From €300EUR$338USD£261GBP
- Clinical Trials
- January 2024
- 60 Pages
Global
From €1426EUR$1,500USD£1,198GBP
- Drug Pipelines
- December 2019
- 74 Pages
Global
From €3327EUR$3,500USD£2,795GBP
- Report
- May 2022
- 49 Pages
Global
From €2377EUR$2,500USD£1,997GBP
- Report
- May 2022
- 40 Pages
Global
From €2377EUR$2,500USD£1,997GBP
CD154, also known as CD40 ligand, is a type of protein found on the surface of certain cells. It is involved in the regulation of the immune system and is a key target for oncology drugs. CD154 is expressed on the surface of T-cells, B-cells, and macrophages, and is involved in the activation of these cells. It is also expressed on the surface of tumor cells, and is thought to play a role in tumor progression.
CD154 is a promising target for oncology drugs, as it is involved in the regulation of the immune system and is expressed on the surface of tumor cells. Several companies are developing drugs that target CD154, including Merck, Bristol-Myers Squibb, and AstraZeneca. These companies are researching and developing drugs that target CD154 in order to treat various types of cancer, including breast, lung, and prostate cancer. Show Less Read more
